METABOLISM OF YM155 MONOBROMIDE, A NOVEL SURVIVIN SUPPRESSANT: IN VITRO SPECIES COMPARISON AND IDENTIFICATION OF METABOLITES IN RATS

被引：0

作者：

Sohda, Kin-ya ^{[1
]}

Suzuki, Katsuhiro ^{[1
]}

Nakamura, Eiji ^{[2
]}

Minematsu, Tsuyoshi ^{[1
]}

Hashimoto, Tadashi ^{[1
]}

Imai, Harumitsu ^{[1
]}

Usui, Takashi ^{[1
]}

Kawamura, Akio ^{[1
]}

Kamimura, Hidetaka ^{[1
]}

机构：

[1] Astellas Pharma Inc, Drug Metab Res Labs, Tokyo, Japan

[2] Astellas Res Serv Co Ltd, Drug Anal & Metab Res Dept, Tokyo, Japan

来源：

DRUG METABOLISM REVIEWS | 2007年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

356

引用

页码：253 / 254

页数：2

共 50 条

[31] YM155, a novel survivin suppressant, demonstrates activity in subjects with hormone refractory prostate cancer (HRPC) previously treated with taxane chemotherapy
Tolcher, A. W.
Karavasilis, V.
Hudes, G.
Quinn, D.
Ferrari, A.
Kocak, I.
Mita, A.
Buell, D.
Keating, A.
Bartels, P.
Charleston, D.
DeBono, J.
ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
[32] Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model
Murakami, Yoshihiro
Matsuya, Takahiro
Kita, Aya
Yamanaka, Kentaro
Noda, Akihiro
Mitsuoka, Keisuke
Nakahara, Takahito
Miyoshi, Sosuke
Nishimura, Shintaro
NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (02) : 221 - 226
[33] Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan
Nakagawa, K.
Satoh, T.
Okamoto, I.
Miyazaki, M.
Morinaga, R.
Tsuya, A.
Hasegawa, Y.
Terashima, M.
Ueda, S.
Fukuoka, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[34] YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Nakahara, Takahito
Takeuchi, Masahiro
Kinoyama, Isao
Minematsu, Tsuyoshi
Shirasuna, Kenna
Matsuhisa, Akira
Kita, Aya
Tominaga, Fumiko
Yamanaka, Kentaro
Kudoh, Masafumi
Sasamata, Masao
CANCER RESEARCH, 2007, 67 (17) : 8014 - 8021
[35] Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines
Iwasa, Tsutomu
Okamoto, Isamu
Suzuki, Minoru
Nakahara, Takahito
Yamanaka, Kentaro
Hatashita, Erina
Yamada, Yuki
Fukuoka, Masahiro
Ono, Koji
Nakagawa, Kazuhiko
CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6496 - 6504
[36] The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model
de Haart, Sanne J.
Minnema, Monique C.
Huang, Julie H.
Aarts-Riemens, Tineke
Lokhorst, Henk
Martens, Anton
Mitsiades, Constantine S.
Mutis, Tuna
BLOOD, 2013, 122 (21)
[37] The Survivin Suppressant YM155 Potentiates Chemosensitivity to Gemcitabine in the Human Pancreatic Cancer Cell Line MiaPaCa-2
Yoon, Dok Hyun
Shin, Jae-Sik
Jin, Dong-Hoon
Hong, Seung-Woo
Jung, Kyung A.
Kim, Seung-Mi
Hong, Yong Sang
Kim, Kyu-Pyo
Lee, Jae-Lyun
Suh, Cheolwon
Lee, Jung Shin
Kim, Tae Won
ANTICANCER RESEARCH, 2012, 32 (05) : 1681 - 1688
[38] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
Cheson, Bruce D.
Bartlett, Nancy L.
Vose, Julie M.
Lopez-Hernandez, Andres
Seiz, Amanda L.
Keating, Anne T.
Shamsili, Setareh
CANCER, 2012, 118 (12) : 3128 - 3134
[39] A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors.
Tolcher, A. W.
Antonia, S.
Lewis, L. D.
Mita, A.
Mahany, J., Jr.
Reddy, N. J.
Till, E.
Buell, D.
Keating, T.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 124S - 124S
[40] YM155, a novel survivin suppressant, demonstrates anti-tumor activity in patients with advanced solid tumors and non-Hodgkin's lymphoma
Tolcher, AW
Antonia, S
Lewis, LD
Mita, A
Mahany, JJ
Reddy, NJ
Till, E
Buell, D
Keating, AT
ANNALS OF ONCOLOGY, 2006, 17 : 23 - 23

← 1 2 3 4 5 →